Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer

Oncogenic BRAF(V600E) mutations activate MAP kinase signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer (CRC). In BRAF(V600E) mutant CRCs, treatment failure may be related to BRAF(V600E) -mediated apoptosis resistance that occurs by an as yet...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Kawakami, Hisato, Huang, Shengbing, Pal, Krishnendu, Dutta, Shamit K., Mukhopadhyay, Debabrata, Sinicrope, Frank A.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5136313/
https://ncbi.nlm.nih.gov/pubmed/27765849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0017
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items